Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLITonePLUS Birch Sublingual vs Vestibular Administration
NCT01191359Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Jan 2010
- Primary completion
- Jan 2011
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of birch pollen allergen extract in birch pollen allergy (2 arms), sponsored by ALK-Abelló. Primary endpoint: Pharmacodynamic efficacy of two different administration routes of SLITonePLUS Birch at 36 weeks. Started Jan 2010; status: completed.
02
Drugs
birch pollen allergen extract
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT01191359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01191359.